Ropinirole transdermal - Hisamitsu

Drug Profile

Ropinirole transdermal - Hisamitsu

Alternative Names: HP 3000

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease
  • Phase II Restless legs syndrome

Most Recent Events

  • 05 Sep 2017 Ropinirole transdermal is still in phase III trials for Parkinson's disease (In adults, In the elderly) in Japan (Transdermal) (JapicCTI-152870) (JapicCTI-142748)
  • 07 Jul 2017 Ropinirole transdermal is still under phase II development for Restless legs syndrome in Japan
  • 07 Jul 2017 Hisamitsu Pharmaceutical announces intention to file for regulatory approval in Japan for Parkinson's disease in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top